The latest research by Future Market Insights forecasts an impressive trajectory for the global trichomonas rapid tests market. Projections indicate a notable CAGR of 5.3% during the anticipated period. The market, valued at USD 437.6 Million in 2023, is anticipated to soar to USD 733.0 Million by 2033.
The trichomonas rapid tests market closed at USD 417.3 Million in 2022, showcasing an initial surge. Remarkably, an expected Year-on-Year (Y-o-Y) growth of 4.9% is forecasted for 2023, indicating a continued upward trend in market expansion.
The global prevalence of sexually transmitted diseases (STDs) and sexual polygamy have a substantial impact on the Trichomonas rapid test industry. Considering STDs, including trichomoniasis, are so common over the world, there is a growing demand for rapid and effective diagnostic techniques.
- According to the article published by International Journal of Pregnancy & Child Birth on January 20 2023, a study conducted at General Hospital Dutsin-ma examined 181 high vaginal swab samples. Participants who had four or more sexual partners had the highest prevalence of trichomoniasis (60%), followed by those who had three partners (41%), two partners (31%), and one partner (27%).
Likewise, sexual polygamy, in which individuals have several sexual partners, adds to the transmission and spread of STDs. Because of the increased risk and awareness of STDs among sexually polygamous people, there is an increasing demand for Trichomonas rapid tests.
These tests enable fast identification, diagnosis, and treatment of trichomoniasis, hence reducing infection transmission in sexual polygamous populations and increasing market growth for rapid testing solutions.
Key Takeaways from Market Study:
- By product, rapid test strip contributed around USD 159.1 Million in 2022. These strips are widely used since they provide rapid outcomes, require minimal equipment, and work well in point-of-care situations, which propels the market growth.
- By sample type, vaginal/urethra swab contributed around USD 331.8 Million in 2022. Trichomonas vaginalis can be precisely identified thanks to its practicality, non-invasiveness, and efficacy in collecting samples from the major sites of infection.
- Hospitals contributed around one-third market share globally in 2022, This can be ascribed to the fact that significant population around the globe suffers from diseases, which can be adequately identified in these setting with qualified assistance.
- By region, North America held dominant share in world in 2022 contributing around USD 157.9 Million. The U.S. leads in this region with high prevalence of trichomoniasis.
“The rising cases of STIs and increase in multiple sexual polygamies contribute to its higher demand and global expansion.” opines Sabyasachi Ghosh Associate Vice President at Future Market Insights (FMI) analyst.
Increased Market Attention: Delve into Detailed Trends and Analysis with Our Report!
Market Competition:
The trichomonas rapid test market is highly competitive, with key players including Common Sense Ltd. and Nanjing Liming Bio-products Co., Ltd . These companies are constantly participating in conferences, award competition with their products and launching new products to gain a larger market share, with a focus on affordability, convenience, and effectiveness.
- In August 2018, Exeltis USA Inc. and Common Sense Ltd. entered into a distribution agreement for the distribution VS-Sense test swab produc.
- In January 2018, Nanjing Liming Bio-products Co., Ltd. received accreditation as UNICEF’s supplier.
Key Companies Profiled:
- Sekisui Diagnostics
- Quidel Corporation
- Roche Diagnostics
- Home Health (UK) Ltd,
- Liming Bio
- Orient Gene
- Creative Diagnostics
- Norgen Biotek Corp.
- Cepheid, BD
- cardinal Health
- Jei Daniel Biotech Corp
- Common Sense
- nal von minden GmbH
- Hologic, Inc.
- Abbott
Key Market Segments Covered in Trichomonas Rapid Tests Industry Research:
By Product:
- Cassette Rapid Test Kit
- Rapid Test Strip
- Rapid Test Swab
- Molecule Based Rapid Test Device
By Sample Type:
- Vaginal/Urethra Swab
- Urine
By End User:
- Hospitals
- Diagnostic Laboratories
- Specialty Clinics
- Others
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa (MEA)
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
